Archiving of Chromatograms: FDA provides important Clarification
In the section Questions and Answers on Current Good Manufacturing Practices, the FDA has answered an interesting question about the implementation of 21 CFR Part 211 and Part 11. The point is that some in industry misinterpret one part of the "Guidance for Industry - Part 11, Electronic Records; Electronic Signatures - Scope and Applications" and believe that in all cases paper printouts of electronic records are sufficient to comply with the requirements in 21 CFR Part 211 when testing medicinal products.
In its answer, the FDA specifically writes that for HPLC or GS systems and other computerised systems, the electronic records themselves must be retained. The FDA doesn't consider the printed paper copy of the chromatogram as a true copy of all electronic raw data because important information about the chromatogram would be missing.
Therefore, printed chromatograms only are not sufficient! The electronic data have to be maintained and must be readily available for review, e.g. during an FDA inspection.
The full text (see question 3) can be found in "Questions and Answers on Current Good Manufacturing Practices, Good Guidance Practices, Level 2 Guidance - Records and Reports."
Dr Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
10.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
26.11.2025FDA Warning Letter Highlights Deficiencies in SST and HPLC Practices
13.11.2025Proposed Revision of USP <1225> Published in the Pharmacopeial Forum
13.11.2025Recent Publications Highlighting Topics to be Discussed at PharmaLab 2025
12.11.2025USP seeks early Input on new NMR Method